Sentiment for Ophthotech Corp (NASDAQ:OPHT)

Ophthotech Corp (NASDAQ:OPHT) institutional sentiment increased to 0.81 in 2018 Q4. Its up 0.02, from 0.79 in 2018Q3. The ratio is better, as 21 investment professionals opened new and increased positions, while 26 trimmed and sold stakes in Ophthotech Corp. The investment professionals in our partner’s database now hold: 13.56 million shares, down from 15.12 million shares in 2018Q3. Also, the number of investment professionals holding Ophthotech Corp in their top 10 positions increased from 0 to 1 for an increase of 1. Sold All: 7 Reduced: 19 Increased: 11 New Position: 10.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. The company has market cap of $57.58 million. The Company’s principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration . It has a 0.82 P/E ratio. The firm is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD.

It closed at $1.39 lastly. It is up 42.86% since May 12, 2018 and is downtrending. It has underperformed by 47.23% the S&P500.

Sabby Management Llc holds 0.54% of its portfolio in IVERIC bio, Inc. for 2.04 million shares. Tang Capital Management Llc owns 600,000 shares or 0.17% of their US portfolio. Moreover, Spark Investment Management Llc has 0.03% invested in the company for 347,800 shares. The New York-based Boothbay Fund Management Llc has invested 0.02% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 1.09 million shares.

Since January 1, 0001, it had 0 buys, and 4 insider sales for $10,340 activity.

More notable recent IVERIC bio, Inc. (NASDAQ:OPHT) news were published by: Businesswire.com which released: “Ophthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors – Business Wire” on January 02, 2019, also Businesswire.com with their article: “Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration – Business Wire” published on October 04, 2018, Globenewswire.com published: “New Research: Key Drivers of Growth for Cinemark, Omega Healthcare Investors, PDC Energy, LiveXLive Media, Ophthotech, and Howard Hughes — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” on April 15, 2019. More interesting news about IVERIC bio, Inc. (NASDAQ:OPHT) were released by: Seekingalpha.com and their article: “Ophthotech acquires Inception 4 in all-stock deal – Seeking Alpha” published on October 31, 2018 as well as Businesswire.com‘s news article titled: “Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration – Business Wire” with publication date: November 12, 2018.

IVERIC bio, Inc. (NASDAQ:OPHT) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *